SCHEMBL1902149

SCHEMBL1902149

Cc1ccc(-c2cc(C(=O)Nc3nnc(-c4ccco4)o3)c3cc(Br)ccc3n2)s1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STAT3 P40763 5/20 0.63
KMT2A Q03164 6/20 0.57
MEN1 O00255 5/20 0.57
RXFP1 Q9HBX9 4/20 0.57
NPC1 O15118 4/20 0.57
KDM4E B2RXH2 5/20 0.54
HPGD P15428 4/20 0.54
L3MBTL1 Q9Y468 3/20 0.54
ALDH1A1 P00352 3/20 0.54
PPARG P37231 2/20 0.54
NCOR2 Q9Y618 2/20 0.54
POLB P06746 2/20 0.54
ALOX15 P16050 2/20 0.54
MAPT P10636 2/20 0.54
TDP1 Q9NUW8 2/20 0.54
ESR1 P03372 1/20 0.54
PLA2G1B P04054 1/20 0.54
RECQL P46063 1/20 0.54
GFER P55789 1/20 0.54
ESR2 Q92731 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1900513 0.87 STAT3 (0.81) STAT3KMT2AMEN1RXFP1NPC1
SCHEMBL1899382 0.82 STAT3 (0.82) STAT3KMT2AMEN1RXFP1NPC1
SCHEMBL1897367 0.82 STAT3 (0.57) STAT3KMT2AMEN1NPC1KDM4E
SCHEMBL1900227 0.81 STAT3 (0.81) STAT3KMT2AMEN1RXFP1NPC1
SCHEMBL1898646 0.80 STAT3 (0.78) STAT3KMT2AMEN1RXFP1KDM4E
SCHEMBL1897448 0.80 STAT3 (0.81) STAT3KMT2AMEN1NPC1KDM4E
SCHEMBL1897499 0.79 STAT3 (0.77) STAT3KMT2AMEN1NPC1KDM4E
SCHEMBL1897496 0.78 STAT3 (0.81) STAT3KMT2AMEN1NPC1KDM4E
SCHEMBL1899815 0.78 STAT3 (1.00) STAT3KMT2AMEN1NPC1KDM4E
SCHEMBL1905449 0.78 STAT3 (0.84) STAT3KMT2AMEN1NPC1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2325181-B1 STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT GENERAL INCORPORATED ASS PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) 2017-03-29 EP disclosed
US-8466290-B2 STAT3 inhibitor containing quinolinecarboxamide derivative as active ingredient PHARMA IP GENERAL INCORPORATED ASSOCIATION (JP) 2013-06-18 US disclosed
US-20110172429-A1 STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT PHARMA IP GENERAL INCORPORATED ASSOCIATION (JP) 2011-07-14 US disclosed
EP-2325181-A1 STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT Pharma Ip General Incorporated Association (JP) 2011-05-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172429-A1 STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT STAT3, STAT4, STAT5B STAT3 1/4885KMT2A 255/4885MEN1 4247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.